Clinical Trials Browser

Completed × INDUSTRY × sotigalimab × Clear all

NCT03123783 2023-12-26

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Phase 1/2 Completed

140 enrolled 16 charts

DermatologicThoracic

Lung Neoplasms, Melanoma, Neoplasms

NCT02482168 2023-12-20

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Phase 1 Completed

DermatologicGenitourinaryHead & Neck

Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma, Neoplasms